Atlas Trials

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Clinical trial NCT03932526 · UNKNOWN

Trial details

NCT number
NCT03932526
Sponsor
Liaoning Cancer Hospital & Institute
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Triple-negative Breast Cancer
Start date
2019-06-24
Primary completion
2022-12-12
Enrollment
184

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.